Back to search results

Understanding Acceptance of DNA Testing for Endometrial Cancer

This study is looking at how women feel about using DNA from a vaginal fluid sample to detect endometrial cancer early. It's an observational study, meaning you won't receive any new treatments. We are looking for Black women, aged 45 or older, who have an intact uterus and have experienced abnormal uterine or post-menopausal bleeding (like bleeding between periods or after menopause). The main goal is to understand how acceptable this method of collecting a sample is to participants. The study plans to enroll 25 participants, but its current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 25 participants. It is not specified if it is randomized or blinded.
What's involved
You would participate in a 30-minute virtual interview at baseline to discuss your feelings about vaginal fluid collection. You would also be willing to participate in a 45-minute activity.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Baseline, which is a 30-minute virtual interview. No further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07527143

Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer

Recruiting
Not specifiedAges 45+Observational
Mayo Clinic
~25 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acceptability of vaginal fluid collection for a DNA-based early detection endometrial cancer test
Measured over Baseline (30-minute virtual interview)

Conditions

Endometrial Carcinoma

Explore related trials

Endometrial Carcinoma

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Shariska Harrington, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Self-identified Black individuals ≥ 45 years with an intact uterus
Assigned female sex at birth
Experience with abnormal uterine or post-menopausal bleeding (defined as vaginal bleeding between periods, heavy vaginal bleeding, vaginal bleeding after menopause, and/or red, brown, or pink colored vaginal discharge after menopause)
Willing to participate in a 45-minute virtual interview

Exclusion

Previous or current diagnosis of endometrial cancer

What this trial measures

  • Acceptability of vaginal fluid collection for a DNA-based early detection endometrial cancer testBaseline (30-minute virtual interview)

    Information collected during a 30-minute virtual interview using mostly open-ended questions. The interviews will be transcribed and reviewed by the study team to identity themes and create coding categories. Coding categories will be used to organize the data into subthemes. Results will be reported in aggregate. Aggregate results will be disseminated to participants if they elect to receive them.